Carl June about the potential of using CAR T therapy to treat glioblastoma – Penn Medicine

Penn Medicine shared a post on LinkedIn:

“This year could see major breakthroughs in brain cancer treatment.

Carl June, MD, the Richard W. Vague Professor in Immunotherapy, spoke about the potential of using CAR T therapy to treat glioblastoma, a rare and aggressive form of brain cancer that carries a median survival time of 15-18 months.

“I think about five years down the line, we’re going to have FDA-approved CARs for glioblastoma,” he said.”

Read the full interview.

Source: Penn Medicine /LinkedIn